Literature DB >> 436517

A rational approach to ligation of patent ductus arteriosus in the neonate.

N W Salomon, R M Anderson, J G Copeland, H D Allen, S J Goldberg, D J Sahn.   

Abstract

During a 23-month period, 25 premature infants underwent ligation of a patent ductus arteriosus performed in the neonatal intensive care unit utilizing a limited posterolateral muscle-retracting incision. This approach afforded adequate exposure with minimal surgical time and trauma. All infants manifested severe respiratory distress and congestive heart failure. Both standard and contrast echocardiographic studies were used for noninvasive preoperative evaluation. Echocardiographic study proved to be a highly reliable and sensitive indicator of ductal patency. Eight infants (32 percent) died at 8 to 225 days of age. The primary cause of death was progressive pulmonary disease with subsequent failure of multiple organ systems. Seventeen (68 percent) of the 25 infants survived to leave the hospital. Advantages of ligation of a patent ductus arteriosus in the neonatal intensive care unit include the elimination of problems of transportation (thermoregulation, ventilation, and loss of lines) and continuity of ongoing care and monitoring. The standard facilities of the neonatal intensive care unit proved completely satisfactory for ligation of a patent ductus arteriosus. Ligation in the neonatal intensive care unit is suggested to minimize potential complications of care in the operating room and transport of these critically ill infants.

Entities:  

Mesh:

Year:  1979        PMID: 436517     DOI: 10.1378/chest.75.6.671

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  2 in total

1.  Patent ductus arteriosus in premature infants.

Authors:  P K Ghosh; J Lubliner; M Mogilner; V Yakirevich; B A Vidne
Journal:  Tex Heart Inst J       Date:  1986-03

2.  Ligation of patent ductus arteriosus in very low birthweight premature neonates.

Authors:  P K Ghosh; J Lubliner; M Mogilnar; V Yakirevich; B A Vidne
Journal:  Thorax       Date:  1985-07       Impact factor: 9.139

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.